Precigen, Inc. (NASDAQ:PGEN - Get Free Report) saw an uptick in trading volume on Wednesday . 1,162,796 shares traded hands during trading, a decline of 18% from the previous session's volume of 1,424,528 shares.The stock last traded at $1.89 and had previously closed at $1.70.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on PGEN. Cantor Fitzgerald reissued an "overweight" rating on shares of Precigen in a report on Thursday, May 15th. HC Wainwright restated a "buy" rating and issued a $6.00 target price on shares of Precigen in a research report on Thursday, March 20th. JMP Securities restated a "market outperform" rating and issued a $6.00 target price on shares of Precigen in a research report on Thursday, June 12th. Finally, Wall Street Zen upgraded Precigen from a "sell" rating to a "hold" rating in a research report on Saturday.
Read Our Latest Stock Analysis on Precigen
Precigen Stock Performance
The stock has a 50-day moving average of $1.46 and a two-hundred day moving average of $1.48. The company has a market cap of $540.18 million, a P/E ratio of -3.27 and a beta of 1.78.
Precigen (NASDAQ:PGEN - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Precigen had a negative return on equity of 279.20% and a negative net margin of 3,728.87%. The company had revenue of $1.34 million during the quarter, compared to the consensus estimate of $0.50 million. As a group, sell-side analysts forecast that Precigen, Inc. will post -0.32 EPS for the current fiscal year.
Institutional Trading of Precigen
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new stake in Precigen in the fourth quarter valued at approximately $27,000. Envestnet Asset Management Inc. lifted its position in Precigen by 29.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 5,915 shares during the last quarter. Apella Capital LLC bought a new stake in Precigen in the first quarter valued at approximately $40,000. Boothbay Fund Management LLC bought a new stake in Precigen in the fourth quarter valued at approximately $35,000. Finally, Voya Investment Management LLC lifted its stake in Precigen by 142.9% in the first quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 21,633 shares during the period. Institutional investors own 33.51% of the company's stock.
About Precigen
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
See Also
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
